Preclinical imaging for drug discovery and development

Advances in multimodal preclinical imaging enable tracking of physiologic and structural changes together in vivo, for highly efficient longitudinal studies of disease progress and drug distribution, delivery and therapeutic response. Same-session X-ray, PET, SPECT, and/or optical views - automatically co-registered - provide detailed anatomic context for physiological metrics such as candidate biomarkers. Advanced software and techniques like spectral unmixing enable tracking of multiple measures together - for example, quantifying critical gene and protein expression, or co-locating a drug compound and its target.

Bruker's modular multimodal imaging systems let you choose which modalities to use with the option to add modalities as needed later, all within the same, small footprint. For highly detailed anatomic and functional studies, Bruker MRI and magnetic particle imaging systems provide outstanding spatial and time resolution, and complement clinical imaging methods for rapid translation of study results between animals and patients.

Learn more about preclinical imaging methods for drug discovery and development.

Read more